Addiction
February 15, 2023
Zhen-Xiang Gao, T. Winhusen, Maria P Gorenflo et al.
Background and aims: Cocaine use disorder (CUD) is a significant public health issue for which there is no Food and Drug Administration (FDA) approved medication. Drug repurposing looks for new cost-effective uses of approved drugs. This study presents an integrated strategy to identify repurposed FDA-approved drugs for CUD treatment. Design: Our drug repurposing strategy combines artificial...
Frontiers in Cellular Neuroscience
February 15, 2023
Cui-Hong Zhou, Xinxin Zhao, Xinxu Ma et al.
Introduction: Compelling evidence indicates that a single sub-anesthetic dose of (S)-ketamine elicits rapid and robust antidepressant effects. However, the underlying mechanisms behind the antidepressant effects of (S)-ketamine remain unclear. Methods: Here, using a chronic variable stress (CVS) model in mice, we analyzed changes inthe lipid compositions of the hippocampus and prefrontal cortex...
European Archives of Psychiatry and Clinical Neuroscience
February 14, 2023
Kenji Hashimoto
40 citations
Cognitive impairment has been observed in patients with various psychiatric disorders, including schizophrenia, major depressive disorder (MDD), and bipolar disorder (BD). Although modern therapeutic drugs can improve certain symptoms (i.e., psychosis, depression) in these patients, these drugs have not been found to improve cognitive impairment. The N-methyl-D-aspartate receptor antagonist...
bioRxiv Preprint Server
February 5, 2023
Francis Kei Masuda, Yanjun Sun, Emily A Aery Jones et al.
2 citations
preprint
Ketamine, a rapid-acting anesthetic and acute antidepressant, carries undesirable spatial cognition side effects including out-of-body experiences and spatial memory impairments. The neural substrates that underlie these alterations in spatial cognition however, remain incompletely understood. Here, we used electrophysiology and calcium imaging to examine ketamine’s impacts on the medial...
Frontiers in Neuroscience
February 2, 2023
Haiyan Liu, Chengyu Wang, Xiaofeng Lan et al.
Background Dysfunction of the amygdala is the core pathogenesis of major depressive disorder (MDD). However, it remains unclear whether ketamine treatment could modulate characteristics of amygdala-related networks. We aimed to explore the relationship between changes in the resting-state functional connectivity (RSFC) of the amygdala and the treatment of ketamine in MDD patients and to...
Pharmacology, Biochemistry, and Behavior
February 1, 2023
Anna Onisiforou, Polymnia Georgiou, Panos Zanos
Major depression (MDD) is a serious neuropsychiatric disorder afflicting around 16-17 % of the global population and is accompanied by recurrent episodes of sadness and suicidal thoughts. Current pharmacological interventions take several weeks to even months for an improvement in depressive symptoms to emerge, with a significant percentage of individuals not responding to these medications at...
Journal of Clinical Medicine
February 1, 2023
Zhen Zhang, Wen-Hao Zhang, Yin Lu et al.
Background: Patients with Crohn’s disease (CD) undergoing bowel resection often suffer from depression and acute pain, which severely impairs their recovery. We aimed to investigate the effects of S-ketamine preconditioning on postoperative depression in patients with CD undergoing a bowel resection with mild to moderate depression and to observe whether it can relieve postoperative pain and...
The Brown University Psychopharmacology Update
February 1, 2023
Results of a systematic review and meta‐analysis comprising six clinical trials suggest that electroconvulsive therapy (ECT) is more efficacious than ketamine in reducing the severity of depressive symptoms in patients with a major depressive episode. No significant between‐group differences in the prevalence of adverse events were observed. Results of the meta‐analysis were published online...
Neuropharmacology
February 1, 2023
Taro Kato
Conventional antidepressant medications act on monoaminergic systems and have important limitations, including a therapeutic delay of weeks to months and low rates of efficacy. Recently, clinical findings have indicated that ketamine, a dissociative anesthetic that blocks N-methyl-d-aspartate receptor channel activity, causes rapid and long-lasting antidepressant effects. Although the exact...
European Neuropsychopharmacology
February 2023
Natalia Malikowska‐racia, Joanna Gołębiowska, Agnieszka Nikiforuk et al.
(S)-ketamine-induced rapid-acting antidepressant effects have revolutionized the pharmacotherapy of major depression; however, this medication also produces psychotomimetic effects such as timing distortion. While (R)-ketamine produces fewer dissociative effects, its antidepressant actions are less studied. Depression is associated with time overestimation (i.e., subjectively, time passes...